Shanghai, July 19, 2024 - WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced that it has been included in the FTSE4Good Index Series for the second consecutive year. This achievement recognizes WuXi AppTec's exceptional performance in environmental, social, and governance (ESG) practices driven by our commitment to advancing sustainability and enabling innovation for a healthier world.

Created by the global index and data provider FTSE Russell, the FTSE4Good Index Series is designed to measure the performance of companies demonstrating strong ESG practices. FTSE Russell evaluations are based on performance in areas such as Corporate Governance, Health & Safety, Anti-Corruption and Climate Change. Businesses included in the FTSE4Good Index Series meet a variety of environmental, social and governance criteria. FTSE Russell’s independent assessment scored WuXi AppTec above global industry standards.

“We are delighted to be recognized by the FTSE4Good Index Series for our exceptional ESG performance,” said Edward Hu, Vice Chairman of WuXi AppTec and Chairman of WuXi AppTec’s ESG Committee. “WuXi AppTec remains steadfast in its commitment to prioritize ESG initiatives and sustainable operations while delivering for our customers worldwide. Through our unique CRDMO and CTDMO business models, we continue to support customers’ needs by developing and delivering innovative new therapies to patients worldwide, working together towards a healthier and more sustainable future.”

As an enabler of innovation, a trusted partner, and a contributor to the global pharmaceutical and life sciences industry, WuXi AppTec integrates ESG priorities in all aspects of its business operations. In 2024, WuXi AppTec joined the United Nations Global Compact (UNGC) in support of its ten sustainability principles and joined the Science Based Targets initiative (SBTi) to reduce carbon emissions in 2023. In 2023 and 2024, WuXi AppTec was named to the S&P Global Sustainability Yearbook and recognized as an Industry and Regional “Top-Rated” company by Sustainalytics. WuXi AppTec’s outstanding ESG performance has been widely acknowledged by major global ESG rating agencies, including MSCI, CDP, and EcoVadis.

About WuXi AppTec

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the third consecutive year in 2023 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."